Mogrify appoints 15 new staff including, Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer

20 May 2019, Cambridge, UK: STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, today announced that it has raised an additional
£14 million bringing the total Series A financing to £30 million.

The financing includes funding from new investor, Seroba Life Sciences (“Seroba”). STORM’s existing investors, Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group also participated in the fundraise.

Boyds, the leading consultancy business that supports the development of pharmaceutical and biotech products for patient benefit, has reported record-breaking growth in its overseas turnover in the 12-months since it was recognised with one of the UK’s most prestigious awards, The Queen’s Awards for Enterprise.

Synpromics Ltd, the leader in gene control, and Lonza Pharma & Biotech announce a partnership for the commercialisation of a number of inducible promoters to improve the manufacturing of biopharmaceuticals. The commercial agreement with Lonza follows the award of an Innovate UK grant to Synpromics announced on 23 April 2018. Lonza and Synpromics worked together to develop and test these innovative promoters in Lonza’s industry-leading GS Xceed® Expression System.

14 May 2019: Norwich Plant Bioscience Ltd (PBL) and Leaf Expression Systems Ltd (Leaf) are delighted to announce a further development in their relationship, with PBL granting Leaf the exclusive rights to sub-license the Hypertrans® transient expression system, the core technology underpinning Leaf’s biologics and vaccines contract development and manufacturing services business. Apart from rights previously granted to PBL’s pre-existing licensees, this effectively transfers to Leaf full control of the Hypertrans® technology and associated patented intellectual property.

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical and healthcare sectors, has introduced a cell based bioassay service to meet rising demand for potency assessments.

Driving innovation into state-of-the-art technologies such as Artificial Intelligence and Complex Cell Models is key to maintaining the UK’s global competitiveness

Today [13 May 2019], Medicines Discovery Catapult and the BioIndustry Association unveil their 2019 State of the Discovery Nation report, providing new insights into the UK’s growing medicines discovery industry.

In support of its continuing growth plans, Boyds, the leading consultancy business that supports the development of pharmaceutical and biotech products for patient benefit, has appointed a new CMC regulatory affairs professional.

Claire Scruton joins Boyds as Senior Manager of CMC Regulatory Affairs and will be based at the organisation’s Cambridge office.

Cell encapsulation for transport of cells and tissues at room temperature

Cambridge, UK and Newcastle, UK, 9th May 2019 / Sciad Newswire / Atelerix, creator of an innovative cell encapsulation technology, today announces it has closed a second round of funding of £700,000 to accelerate development of its cell transport products to market.

Today [9 May], Medicines Discovery Catapult and LifeArc, leading forces driving UK innovation in drug discovery, announce their strategic partnership.

The identification and development of novel biomarkers that detect efficacy and safety of novel drug molecules, which can be used in human trials, will be the focus of the partnership.